High ITGA2 expression is associated with lower complete remission rates and shorter overall survival in AML patients, with levels dropping in remission and rising at relapse, indicating its role as a poor prognostic marker; additionally, α2β1-mediated adhesion to collagen I in T-ALL cells reduces doxorubicin-induced apoptosis, contributing to chemo-resistance [34]. The gene discussed is ITGA2; the disease is acute myeloid leukemia.